Conmed (CNMD) Tops Q2 EPS by 3c ; Offers Guidance
Tweet
Share
E-mailGet Alerts CNMD Hot Sheet
Price: $49.82 +0.69%
Financial Fact:
Research and development expense: 8.35M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Research and development expense: 8.35M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Conmed (NYSE: CNMD) reported Q2 EPS of $1.15, $0.03 better than the analyst estimate of $1.12. Revenue for the quarter came in at $342.34 million versus the consensus estimate of $338.4 million.
GUIDANCE:
Conmed sees FY2025 revenue of $1.36-1.39 billion, versus the consensus of $1.36 billion.
For earnings history and earnings-related data on Conmed (CNMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c
- Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
